{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T10:25:29Z","timestamp":1785925529904,"version":"3.56.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"This work was supported by the imCORE Network on behalf of F. Hoffmann-La Roche (ASA-1 project).","award":["ASA-1 project"],"award-info":[{"award-number":["ASA-1 project"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"DOI":"10.1186\/s13073-026-01680-4","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T06:14:47Z","timestamp":1780121687000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dynamics of tumor ecosystems and microbiome in response to neoadjuvant ABFOLFOX treatment in patients with unresectable colorectal cancer with liver metastasis"],"prefix":"10.1186","volume":"18","author":[{"given":"Wonkyung","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Sang","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Wook","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Sung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Ho","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti","family":"Nagarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allyson","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8567-456X","authenticated-orcid":false,"given":"Chang Ohk","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5886-3920","authenticated-orcid":false,"given":"Sun Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"1680_CR1","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","volume":"23","author":"LA Diaz","year":"2022","unstructured":"Diaz LA, Shiu K-K, Kim T-W, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022;23:659\u201370.","journal-title":"Lancet Oncol"},{"key":"1680_CR2","doi-asserted-by":"publisher","unstructured":"Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, Garc\u00eda-Alfonso P, Neyns B, Luppi G, Cardin DB et al. First-line Nivolumab plus low-dose Ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase II checkmate 142 study. J Clin Oncol. 2021. https:\/\/doi.org\/10.1200\/JCO.21.01015.","DOI":"10.1200\/JCO.21.01015"},{"key":"1680_CR3","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","volume":"20","author":"C Eng","year":"2019","unstructured":"Eng C, Kim TW, Bendell J, Argil\u00e9s G, Tebbutt NC, Di Bartolomeo M, Falcone A, Fakih M, Kozloff M, Segal NH, et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019;20:849\u201361.","journal-title":"Lancet Oncol"},{"key":"1680_CR4","doi-asserted-by":"publisher","unstructured":"Kawazoe A, Xu RH, Garc\u00eda-Alfonso P, Passhak M, Teng HW, Shergill A, Gumus M, Qvortrup C, Stintzing S, Towns K et al. Lenvatinib plus Pembrolizumab versus standard of care for previously treated metastatic colorectal cancer: final analysis of the randomized, open-label, phase III leap-017 study. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.23.02736.","DOI":"10.1200\/JCO.23.02736"},{"key":"1680_CR5","first-page":"735","volume":"16","author":"F Battaglin","year":"2018","unstructured":"Battaglin F, Naseem M, Lenz HJ, Salem ME. Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives. Clin Adv Hematol Oncol. 2018;16:735\u201345.","journal-title":"Clin Adv Hematol Oncol"},{"key":"1680_CR6","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.intimp.2010.12.024","volume":"11","author":"T Chan","year":"2011","unstructured":"Chan T, Wiltrout RH, Weiss JM. Immunotherapeutic modulation of the suppressive liver and tumor microenvironments. Int Immunopharmacol. 2011;11:879\u201389.","journal-title":"Int Immunopharmacol"},{"key":"1680_CR7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","volume":"5","author":"PC Tumeh","year":"2017","unstructured":"Tumeh PC, Hellmann MD, Hamid O, Tsai KK, Loo KL, Gubens MA, Rosenblum M, Harview CL, Taube JM, Handley N, et al. Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res. 2017;5:417\u201324.","journal-title":"Cancer Immunol Res"},{"key":"1680_CR8","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s10585-023-10217-7","volume":"40","author":"BW Tian","year":"2023","unstructured":"Tian BW, Han CL, Wang HC, Yan LJ, Ding ZN, Liu H, Mao XC, Tian JC, Xue JS, Yang LS, et al. Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysis. Clin Exp Metastasis. 2023;40:255\u201387.","journal-title":"Clin Exp Metastasis"},{"key":"1680_CR9","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1001\/jamaoncol.2022.7845","volume":"9","author":"M Fakih","year":"2023","unstructured":"Fakih M, Sandhu J, Lim D, Li X, Li S, Wang C, Regorafenib. Ipilimumab, and Nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy: a phase 1 nonrandomized clinical trial. JAMA Oncol. 2023;9:627\u201334.","journal-title":"JAMA Oncol"},{"key":"1680_CR10","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","volume":"52","author":"WS Lee","year":"2020","unstructured":"Lee WS, Yang H, Chon HJ, Kim C. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med. 2020;52:1475\u201385.","journal-title":"Exp Mol Med"},{"key":"1680_CR11","doi-asserted-by":"publisher","first-page":"6171","DOI":"10.1158\/0008-5472.CAN-10-0153","volume":"70","author":"RK Shrimali","year":"2010","unstructured":"Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010;70:6171\u201380.","journal-title":"Cancer Res"},{"key":"1680_CR12","unstructured":"Aronesty E. ea-utils: Command-line tools for processing biological sequencing data. GitHub. 2011. https:\/\/github.com\/ExpressionAnalysis\/ea-utils.\u00a0"},{"key":"1680_CR13","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1680_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.","journal-title":"BMC Bioinformatics"},{"key":"1680_CR15","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325.","journal-title":"Cell Syst"},{"key":"1680_CR16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","volume":"1711","author":"B Chen","year":"2018","unstructured":"Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243\u201359.","journal-title":"Methods Mol Biol"},{"key":"1680_CR17","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Saut\u00e8s-Fridman C, Fridman WH, de Reyni\u00e8s A. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17:218.","journal-title":"Genome Biol"},{"key":"1680_CR18","doi-asserted-by":"publisher","first-page":"e15543","DOI":"10.1371\/journal.pone.0015543","volume":"5","author":"Y Hoshida","year":"2010","unstructured":"Hoshida Y. Nearest template prediction: a single-sample-based flexible class prediction with confidence assessment. PLoS ONE. 2010;5:e15543.","journal-title":"PLoS ONE"},{"key":"1680_CR19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12943-024-02005-y","volume":"23","author":"H Gao","year":"2024","unstructured":"Gao H, Xi Z, Dai J, Xue J, Guan X, Zhao L, Chen Z, Xing F. Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in cancers: new directions and therapeutic options. Mol Cancer. 2024;23:88.","journal-title":"Mol Cancer"},{"key":"1680_CR20","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/s42255-023-00854-3","volume":"5","author":"M Ji","year":"2023","unstructured":"Ji M, Xu X, Xu Q, Hsiao YC, Martin C, Ukraintseva S, Popov V, Arbeev KG, Randall TA, Wu X, et al. Methionine restriction-induced sulfur deficiency impairs antitumour immunity partially through gut microbiota. Nat Metab. 2023;5:1526\u201343.","journal-title":"Nat Metab"},{"key":"1680_CR21","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","volume":"72","author":"A Albillos","year":"2020","unstructured":"Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020;72:558\u201377.","journal-title":"J Hepatol"},{"key":"1680_CR22","doi-asserted-by":"publisher","first-page":"eaay0555","DOI":"10.1126\/sciimmunol.aay0555","volume":"4","author":"CG Kim","year":"2019","unstructured":"Kim CG, Jang M, Kim Y, Leem G, Kim KH, Lee H, Kim T-S, Choi SJ, Kim H-D, Han JW, et al. VEGF-A drives TOX-dependent T cell exhaustion in anti\u2013PD-1\u2013resistant microsatellite stable colorectal cancers. Sci Immunol. 2019;4:eaay0555.","journal-title":"Sci Immunol"},{"key":"1680_CR23","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1158\/0008-5472.CAN-12-2325","volume":"73","author":"M Terme","year":"2013","unstructured":"Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, Dubreuil O, Carpentier AF, Tartour E, Taieb J. VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer. Cancer Res. 2013;73:539\u201349.","journal-title":"Cancer Res"},{"key":"1680_CR24","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S1470-2045(22)00274-1","volume":"23","author":"C Antoniotti","year":"2022","unstructured":"Antoniotti C, Rossini D, Pietrantonio F, Catteau A, Salvatore L, Lonardi S, Boquet I, Tamberi S, Marmorino F, Moretto R, et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2022;23:876\u201387.","journal-title":"Lancet Oncol"},{"key":"1680_CR25","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","volume":"22","author":"PS Hegde","year":"2016","unstructured":"Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res. 2016;22:1865\u201374.","journal-title":"Clin Cancer Res"},{"key":"1680_CR26","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3892\/ol.2023.13967","volume":"26","author":"R Ohkuma","year":"2023","unstructured":"Ohkuma R, Fujimoto Y, Ieguchi K, Onishi N, Watanabe M, Takayanagi D, Goshima T, Horiike A, Hamada K, Ariizumi H, et al. Monocyte subsets associated with the efficacy of anti\u2013PD\u20131 antibody monotherapy. Oncol Lett. 2023;26:381.","journal-title":"Oncol Lett"},{"key":"1680_CR27","doi-asserted-by":"publisher","unstructured":"WuY, Yang S, Ma J, Chen Z, Song G, Rao D, Cheng Y, Huang S, Liu Y, Jiang S et al. Spatiotemporal immune landscape of colorectal cancer liver metastasis at single-cell level. Cancer Discov. 2022;12:134\u201353. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0316.","DOI":"10.1158\/2159-8290.CD-21-0316"},{"key":"1680_CR28","doi-asserted-by":"publisher","unstructured":"TanagalaKKK, Morin-Baxter J, Carvajal R, Cheema M, Dubey S, Nakagawa H, Yoon A, Cheng YL, Taylor A, Nickerson J et al. SP140 inhibits STAT1 signaling, induces IFN-\u03b3 in tumor-associated macrophages, and is a predictive biomarker of immunotherapy response. J Immunother Cancer. 2022;10:e005088. https:\/\/doi.org\/10.1136\/jitc-2022-005088.","DOI":"10.1136\/jitc-2022-005088"},{"key":"1680_CR29","doi-asserted-by":"crossref","unstructured":"van der Werf J, Chin CV, Fleming NI. SnoRNA in cancer progression, metastasis and immunotherapy response. Biology (Basel) 2021;10.","DOI":"10.3390\/biology10080809"},{"key":"1680_CR30","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","volume":"38","author":"RJ Motzer","year":"2020","unstructured":"Motzer RJ, Banchereau R, Hamidi H, Powles T, McDermott D, Atkins MB, Escudier B, Liu LF, Leng N, Abbas AR, et al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. Cancer Cell. 2020;38:803\u2013e174.","journal-title":"Cancer Cell"},{"key":"1680_CR31","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13059-021-02391-2","volume":"22","author":"\u00c9 Fafard-Couture","year":"2021","unstructured":"Fafard-Couture \u00c9, Bergeron D, Couture S, Abou-Elela S, Scott MS. Annotation of snoRNA abundance across human tissues reveals complex snoRNA-host gene relationships. Genome Biol. 2021;22:172.","journal-title":"Genome Biol"},{"key":"1680_CR32","doi-asserted-by":"publisher","first-page":"103866","DOI":"10.1016\/j.ebiom.2022.103866","volume":"76","author":"C Cai","year":"2022","unstructured":"Cai C, Peng Y, Shen E, Wan R, Gao L, Gao Y, Zhou Y, Huang Q, Chen Y, Liu P, et al. Identification of tumour immune infiltration-associated snoRNAs (TIIsno) for predicting prognosis and immune landscape in patients with colon cancer via a TIIsno score model. EBioMedicine. 2022;76:103866.","journal-title":"EBioMedicine"},{"key":"1680_CR33","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41591-022-01695-5","volume":"28","author":"KA Lee","year":"2022","unstructured":"Lee KA, Thomas AM, Bolte LA, Bj\u00f6rk JR, de Ruijter LK, Armanini F, Asnicar F, Blanco-Miguez A, Board R, Calbet-Llopart N, et al. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nat Med. 2022;28:535\u201344.","journal-title":"Nat Med"},{"key":"1680_CR34","doi-asserted-by":"publisher","first-page":"101478","DOI":"10.1016\/j.xcrm.2024.101478","volume":"5","author":"X Kang","year":"2024","unstructured":"Kang X, Lau HC, Yu J. Modulating gut microbiome in cancer immunotherapy: harnessing microbes to enhance treatment efficacy. Cell Rep Med. 2024;5:101478.","journal-title":"Cell Rep Med"},{"key":"1680_CR35","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.chom.2024.06.010","volume":"32","author":"Y Kim","year":"2024","unstructured":"Kim Y, Kim G, Kim S, Cho B, Kim SY, Do EJ, Bae DJ, Kim S, Kweon MN, Song JS, et al. Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor. Cell Host Microbe. 2024;32:1380\u2013e939.","journal-title":"Cell Host Microbe"},{"key":"1680_CR36","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1093\/annonc\/mdu088","volume":"25","author":"G Folprecht","year":"2014","unstructured":"Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F, Hartmann JT, Stoehlmacher-Williams J, Lang H, Trarbach T, et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX\/cetuximab or FOLFIRI\/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol. 2014;25:1018\u201325.","journal-title":"Ann Oncol"},{"key":"1680_CR37","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1093\/annonc\/mdu580","volume":"26","author":"T Gruenberger","year":"2015","unstructured":"Gruenberger T, Bridgewater J, Chau I, Garcia Alfonso P, Rivoire M, Mudan S, Lasserre S, Hermann F, Waterkamp D, Adam R. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2015;26:702\u20138.","journal-title":"Ann Oncol"},{"key":"1680_CR38","doi-asserted-by":"crossref","unstructured":"Kim W, Kim JE, Hong YS, Hwang DW, Kim J, Lee JS, Shin JH, Kim TW, Nagarkar D, Byrd A et al. Gene expression profiling of neoadjuvant ABFOLFOX treatment in patients with unresectable colorectal cancer with liver metastases. GSE330465. NCBI Gene Expression Omnibus. 2026. https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE330465.\u00a0","DOI":"10.1186\/s13073-026-01680-4"},{"key":"1680_CR39","unstructured":"Kim W, Kim JE, Hong YS, Hwang DW, Kim J, Lee JS, Shin JH, Kim TW, Nagarkar D, Byrd A et al. Metagenomic profiling of patients with unresectable colorectal cancer liver metastases treated with neoadjuvant atezolizumab and ABFOLFOX. SRP702262. Sequence Read Archive (SRA). 2024. https:\/\/trace.ncbi.nlm.nih.gov\/Traces\/?study=SRP702262.\u00a0"},{"key":"1680_CR40","unstructured":"Kim W, Kim JE, Hong YS, Hwang DW, Kim J, Lee JS, Shin JH, Kim TW, Nagarkar D, Byrd A et al. Raw RNA sequencing data from 104 colorectal cancer with liver metastasis patients. EGAD50000000954. European Genome-phenome Archive (EGA). 2024. https:\/\/ega-archive.org\/datasets\/EGAD50000000954.\u00a0"},{"key":"1680_CR41","unstructured":"Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Saut\u00e8s-Fridman C, Fridman WH. Reyni\u00e8s Ad. MCPcounter. Github. 2019. https:\/\/github.com\/ebecht\/MCPcounter.\u00a0"},{"key":"1680_CR42","unstructured":"Kim S-H. Analysis of bulk RNAseq data of desmoid tumor and reactive fibrotic tissue. GitHub. 2024. https:\/\/github.com\/caf-lab\/desmoid_RNAseq.\u00a0"},{"key":"1680_CR43","unstructured":"Beghini F, McIver LJ, Blanco-M\u00ecguez A, Dubois L, Asnicar F, Maharjan S, Mailyan A, Thomas AM, Manghi P, Valles-Colomer M et al. HUMAnN. Github. 2024. https:\/\/github.com\/biobakery\/humann.\u00a0"},{"key":"1680_CR44","unstructured":"Wood DE, Lu J, Langmead B. Kraken2. GitHub. 2025. https:\/\/github.com\/DerrickWood\/kraken2.\u00a0"},{"key":"1680_CR45","unstructured":"Lu J, Breitwieser F. Bracken 2.9 abundance estimation. GitHub. 2023. https:\/\/github.com\/jenniferlu717\/Bracken.\u00a0"}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-026-01680-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-026-01680-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-026-01680-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:22:07Z","timestamp":1785882127000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13073-026-01680-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1680"],"URL":"https:\/\/doi.org\/10.1186\/s13073-026-01680-4","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"14 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In cohort A, the study protocol was approved by the Institutional Review Board (IRB) of Asan Medical Center (approval No. 2019-0023), and surgical samples of patients who participated in our biomarker discovery program (approval No. 2011\u2009\u2212\u20090511) were used. In cohort B, the prospective study protocol was also approved by the IRB (approval No. 2018\u2009\u2212\u20091489) and registered to the clinical trial database (NCT03698461). Written informed consent was obtained from all participants for their participation in the study. All study procedures were conducted in accordance with the tenets of the Declaration of Helsinki and Good Clinical Practice.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.B. was a former employee of Genentech\/Roche and is currently affiliated with the Center for Systems Immunology, Benaroya Research Institute, Seattle, WA, USA. D.N was a former employee of Genentech\/Roche and is currently affiliated with R&D Strategic Initiatives, Genmab US Inc, Princeton, New Jersey, USA. S.Y.K reports grants from Roche\/Genentech during the conduct of this study. T.W.K reports grants from Roche\/Genentech, USA and Genome Insight, Inc., South Korea during the conduct of this study. The remaining authors have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"117"}}